Speciality: Hematology
Description:
A warm welcome to all the medical professionals to this session on "Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective." This session synthesizes the key takeaways from our discussion on ferric maltol, highlighting its transformative potential in the management of iron deficiency anemia (IDA). The overarching new perspective is a shift away from the traditional, one-size-fits-all approach to oral iron supplementation, toward a more nuanced and patient-focused strategy.
The primary limitation of standard oral iron salts is their high incidence of gastrointestinal (GI) side effects, which leads to poor patient adherence and treatment failure. Ferric maltol provides a new perspective by addressing this issue directly. Its unique chemical structure, a stable complex of ferric iron (Fe³⁺) and maltol, minimizes the release of free iron in the gut, thereby reducing GI irritation and inflammation. This improved tolerability is not just a secondary benefit; it is a core feature that can lead to better treatment compliance and, ultimately, more effective iron repletion.
In conclusion, the new perspective is that ferric maltol is not simply another oral iron option, but a clinically meaningful alternative that overcomes the historical drawbacks of traditional oral iron. Its proven efficacy and favorable tolerability profile, particularly in challenging patient populations like those with inflammatory bowel disease or chronic kidney disease, position it as a valuable tool in the modern management of IDA. This allows clinicians to choose a therapy that is both effective and well-tolerated from the outset, leading to a better quality of life for patients.
See More Webinars @ Hidoc Webinars
1.
After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.
2.
Why breast cancer survivors don't take their medicine, and what can be done about it.
3.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
4.
C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.
5.
Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.
1.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
2.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
3.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
4.
Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?
5.
What Is Degos Disease? A Comprehensive Overview Of Symptoms, Diagnosis, and Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIII
2.
Efficient Management of First line ALK-rearranged NSCLC - Part II
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation